Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05256316 · ClinicalTrials.gov registry record
Risks of Bacterial and Fungal Superinfection in Patients With COVID-19
A clinical trial, sponsored by The University of Queensland.
- Completed
- Registry status
- 790
- Enrollment target
NCT05256316: Completed study, sponsored by The University of Queensland.
NCT05256316 is a clinical trial that has completed, run by The University of Queensland. The registered enrollment target is 790 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05256316 has completed, sponsored by The University of Queensland.
- COMPLETED
- Registry status
- 790 participants
- Enrollment target
Study Summary
Infection with bacteria or fungi can be deadly. Often, these types of infections can lead to an increase in the severity of illness requiring intensive care unit (ICU) admission, prolonged duration of treatment and further risks associated with additional infections and superinfections. These are also called hospital acquired secondary infections. Patients who contract COVID-19 and require an ICU admission are at increased risk of contracting these secondary infections, and receive certain medications that can lower your body's immune response. In COVID-19 patients who require these treatments, it is unclear what affect these medications can have on developing an additional infection as well as the rate of recovery/survival. This study is evaluating the effect these medications have on the development of secondary infections and rate of survival of COVID-19 patients that have been admitted to ICUs.
Primary Outcome
Data collected from medical records of patients will include demographics, medical history, details of bacterial and fungal infections in the first 60 days after admission (includes aetiological pathogen, sample isolated from and antimicrobial susceptibility), treatment received for COVID-19 with antiviral or immunomodulatory therapy and disposition at 60 days from hospital admission
Interventions
- OTHER Previously admitted COVID-19 patients in intensive care units
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 790 participants |
| Start Date | 2022-02-14 |
| Est. Completion | 2022-12-04 |
What the finished NCT05256316 record still lists
NCT05256316 is an observational study that tracks outcomes without assigning an intervention. The registered 790 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Previously admitted COVID-19 patients in intensive care units is the first listed.
NCT05256316 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05256316 about?
NCT05256316 is a clinical study titled "Risks of Bacterial and Fungal Superinfection in Patients With COVID-19". Infection with bacteria or fungi can be deadly. Often, these types of infections can lead to an increase in the severity of illness requiring intensive care unit (ICU) admission, prolonged duration of treatment and further risks associated with additional infections and superinfections. These are al...
What is the current status of trial NCT05256316?
This trial is currently completed. The enrollment target is 790 participants. The study started on 2022-02-14. Estimated completion is 2022-12-04.
What interventions are being tested in trial NCT05256316?
The interventions under investigation include: Previously admitted COVID-19 patients in intensive care units (OTHER).
Who is sponsoring clinical trial NCT05256316?
This trial is sponsored by The University of Queensland, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04967989 · 790 participants · Phase 3
Clarifying the Optimal Application of SLT Therapy Trial
- NCT06162611 · 790 participants · Phase 4
Etonogestrel (ENG) Implant Insertion for Emergency Contraception With Oral Levonorgestrel (LNG) vs Placebo
- NCT03424005 · 792 participants · Phase 1
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
- NCT05866081 · 792 participants · NA
Stent Omission After Ureteroscopy and Lithotripsy in the Michigan Urological Surgery Improvement Collaborative
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI